BC Week In Review | Sep 21, 2015
Company News

Amgen, NantWorks deal

Amgen granted NantWorks’ NantPharma LLC subsidiary exclusive, worldwide rights to develop and commercialize AMG 337 , excluding Japan, Russia and certain countries in central Asia. AMG 337, a small molecule inhibitor of c-Met receptor tyrosine kinase...
BC Extra | Sep 15, 2015
Company News

NantPharma licenses Amgen's AMG 337

Amgen Inc. (NASDAQ:AMGN) granted NantPharma LLC exclusive, worldwide rights to develop and commercialize AMG 337 , excluding Japan, Russia and certain countries in central Asia. NantPharma is one of several subsidiaries of Patrick Soon-Shiong's NantWorks LLC...
BioCentury | Jun 17, 2013
Strategy

Grounded in Japan

Amgen Inc. has been developing products in Japan via JVs and partnerships since the early 1980s. Now a new joint venture with Astellas Pharma Inc. will allow the biotech to build its first commercial presence...
BC Week In Review | Jun 3, 2013
Company News

Amgen, Astellas deal

The companies formed a JV, Amgen Astellas BioPharma KK (Tokyo, Japan), to co-develop and co-commercialize five Amgen compounds in Japan. The JV will be responsible for the development and commercialization of the compounds in Japan....
BC Extra | May 30, 2013
Company News

Amgen, Astellas form Japanese JV for Amgen compounds

Amgen Inc. (NASDAQ:AMGN) and Astellas Pharma Inc. (Tokyo:4503) formed a JV, Amgen Astellas BioPharma KK, to co-develop and co-commercialize five Amgen compounds in Japan. The JV will be responsible for the development and commercialization of...
Items per page:
1 - 5 of 5